Christmas came early for cannabis research scientists. The U.S. Drug Enforcement Agency (DEA) decided to ease some of the regulatory requirements that had been imposed on those who were conducting FDA-approved clinical trials on cannabidiol (CBD).
“This is certainly a step in the right direction towards the development and proof of CBD as an empirically efficacious compound. These modifications will streamline the research process regarding CBD’s possible medicinal value and help to bolster existing scientific research and studies,” said Seth Yakatan, CEO of Kalytera. Kalytera is one of the leading research companies that is developing synthetic CBD (Cannabidiol) compounds for various ailments including Osteporosis, Prader-Willi Syndrome, and Obesity.
– Read the entire article at Forbes.